Source: https://unapprovedpharmacy.com/2010/11/27/fda-warning-evenbetternow/
Timestamp: 2019-04-20 04:21:44+00:00

Document:
These (and other) products are marketed in violation of provisions of the Federal Food, Drug, and Cosmetic Act (the Act) as described below.
• Toxins play a major role in ALS [Amyotrophic Lateral Sclerosis] and other neurological disorders, so neutralizing these toxins is highly important. Two very easy, inexpensive and effective ways to do this is with EBN® Detoxifying Clay Baths and Bio-Chelat™ Heavy Metal Chelator.
However, these products are drugs, as defined by section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (“the Act”), 21 U.S.C. § 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. Kids Clear Detoxifying Clay Baths and EBN Detoxifying Bentonite Clay are also drugs under section 201(g)(1) of the Act, 21 U.S.C. § 321(g)(1), because they are intended to affect the structure or function of the body and/or intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man. We note that certain versions of Kids Clear Detoxifying Clay Baths and EBN Detoxifying Bentonite Clay represents these products as dietary supplements. To the extent that these products are not intended for ingestion, they are not dietary supplements as defined by section 201(ff) of the Act, 21 U.S.C. § 321(ff).
Moreover, Kids Chelat Heavy Metal Chelator, Bio-Chelat Heavy Metal Chelator, Behavior Balance DMG Liquid, AlkaLife Alkaline Drops, NutriBiotic Grapefruit Seed Extract, Natur-Leaf, Kids Clear Detoxifying Clay Baths, and EBN Detoxifying Bentonite Clay are “new drugs” as defined by section 201(p) of the Act, 21 U.S.C. § 321(p), because they are not generally recognized as safe and effective for use and under the conditions prescribed, recommended, or suggested in its labeling. Under sections 301(d) and 505(a) of the Act, 21 U.S.C. §§ 331(d) and 355(a), new drugs may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for them. FDA-approved applications are not in effect for these products. Thus, the sale of the above-listed products violates these provisions of the Act.
Furthermore, Kids Chelat Heavy Metal Chelator, Bio-Chelat Heavy Metal Chelator, Behavior Balance DMG Liquid, AlkaLife Alkaline Drops, NutriBiotic Grapefruit Seed Extract, Natur-Leaf, Kids Clear Detoxifying Clay Baths, EBN Detoxifying Bentonite Clay are offered for conditions, such as (but not limited to) autism, heavy metal poisoning, and interstitial cystitis, which are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions cannot be written so that a layman can use them safely for their intended uses. Thus, your products’ labeling fails to bear adequate directions for their intended uses, causing them to be misbranded under section 502(f)(1) of the Act, 21 U.S.C. § 352(f)(1). These products are not exempt under 21 C.F.R. §§ 201.100(c)(2) and 201.115 from the requirement that labeling bear adequate directions for use because these products lack approved applications. Section 301(a) of the Act, 21 U.S.C. § 331(a), prohibits the introduction of a misbranded drugs into interstate commerce. Accordingly, the sale of the above-listed products violates these provisions of the Act.
The Heavy Metal Screen Test, used to detect heavy metals in human urine, is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. §351(f)(1)(B), because an approved application for premarket approval (PMA) pursuant to section 515(a) of the Act, § 21 U.S.C. 360e(a) or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. §360j(g), are not in effect for it. The Heavy Metal Screen Test is also misbranded under section 502(o) of the Act, 21 U.S.C. §352(o), in that it was manufactured, prepared, propagated, compounded or processed in an establishment not duly registered under section 510 of the Act, 21 U.S.C. §360; not included in a list required by 510(j), 21 U.S.C. §360(j); and notification or other information respecting the device was not provided to the FDA as required by section 510(k) of the Act, 21 U.S.C. §360(k). The issues and violations cited in this letter are not an all-inclusive statement of violations that exist in connection with your products and websites. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.
You should take prompt action to correct the violations cited in this letter and any other violations you may have. Failure to promptly correct such violations may result in legal action, without further notice, including, without limitation, seizure and injunction. Other federal agencies may take this Warning Letter into account when considering the award of contracts.
If you have any questions about the content of this letter, please contact Dr. William Vitale, Compliance Officer, at 949-608-2919.
A description of the new drug approval process can be found on FDA’s internet website athttp://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm.
Any questions you may have regarding this process should be directed to the Food and Drug Administration, Division of Drug Information, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, WO51-2201, Silver Spring, Maryland 20993.

References: § 321
 § 321
 § 321
 § 321
 § 352
 § 331
 §351
 § 21
 §360
 §352
 §360
 §360
 §360